Taking into account the beneficial effects of RES on hypertension, obesity, inflammation, diabetes and dyslipidemia, RES could constitute an interesting pharmacological approach for the treatment of metabolic syndrome, which is associated with an increased risk of CVD development. Nevertheless, among the points to discuss for the interpretation of preclinical and clinical studies, not only the poor bioavailability and the dose of RES are critical, but also the length of RES treatment and the best time for initiating it (most studies showed effectiveness of RES when it was administered for short periods and as a pretreatment) [67]. Larger controlled human clinical trials are thus needed to investigate these points and to study the effects of long-term RES supplementation. Resveratrol and Cardiovascular Diseases (nih.gov)
In mice resveratrol has lengthened lifespan of obese mice abolishing practically abolishing lifespan negative effects of obesity, it has also lengthened lifespan of aging accelerated mice, of mice with mitochondrial defects, of normal aging but short lived strains of mice, of yeast, of short lived fish, and of a few other species.
It is able to elicit antiaging effects in multiple organs but most strongly in the heart, where iirc, it induces hundreds of gene expression changes opposed to aging and akin to calorie restriction(calorie restriction being one of the strongest youth resilience and health promoting antiaging interventions known.), this has already been shown in animals
Resveratrol presents a therapeutic agent with a novel mechanism of action that appears to benefit a variety of conditions related to CVD and HF. Ongoing studies will test the hypothesis that the addition of resveratrol in meaningful doses can help patients with CVD and/or HF. The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review (nih.gov)
Animal gene expression research
Surprisingly, resveratrol opposed 947 (92%) of age-related changes in gene expression, and 522 of these represented highly significant differences in expression between the old control and old resveratrol groups (P≤0.01). Thus, resveratrol at doses that can be readily achieved through dietary supplementation in humans is as effective as CR in opposing the majority of age-related transcriptional alterations in the aging heart. Because the collection of such alterations in gene expression is a biomarker of aging, our results imply that similar to CR, middle-age onset resveratrol supplementation at low doses is likely a robust intervention in the retardation of cardiac aging. A Low Dose of Dietary Resveratrol Partially Mimics Caloric Restriction and Retards Aging Parameters in Mice (nih.gov)
No comments:
Post a Comment